Active Studies

Alzheimer’s Disease Neuroimaging Initiative 4 Study (ADNI-4)

This observational study aims to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia.

Alzheimer's Disease Research Center (ADRC)

The purpose of the Northwestern Alzheimer’s Disease Research Center (NU ADRC) research registry is to 1) provide state-of-the-art care to patients with mild cognitive impairment, Alzheimer’s disease and related disorders, and to 2) support clinical and basic research on memory and aging collecting, storing, and disseminating clinical data, brain imaging, and biological samples from research participants to collaborators.

Longitudinal Frontotemporal Dementia Study (ALLFTD)

This observational study aims to understand how Frontotemporal Lobar Degeneration (FTLD) syndromes progress over time, and to develop new tools to help with diagnosis and eventual treatment. The study is enrolling patients with FTLD syndromes. Additionally, the study is enrolling healthy members of families where there is a strong family history of FTLD or known FTLD-associated genetic mutation.

AHEAD 3-45 Study

This interventional trial is enrolling participants age 50 to 80 years old who are cognitively normal but have evidence of elevated or somewhat elevated amyloid in the brain. It is a Phase III study to test the efficacy of an anti-amyloid antibody medication (lecanemab) in reducing the levels of amyloid and potentially delaying the onset of cognitive impairment.

Language in Primary Progressive Aphasia

The Language in Primary Progressive Aphasia (PPA) aims to better understand progression in PPA and its link to brain changes, increase awareness of PPA, and identify biomarkers leading to earlier diagnosis and treatment. Participants are asked to undergo tests of language and thinking abilities and have brain scans every two years.

Longitudinal Early-onset Alzheimer's Disease Study (LEADS)

This observational study enrolling participants with young-onset Alzheimer disease (ages 40-64). This study assesses clinical/cognitive measures, imaging, biomarker, and genetic characteristics to look at disease progression in individuals with early onset Alzheimer's disease (EOAD). This includes individuals with mild cognitive impairment or mild dementia due to probable underlying Alzheimer disease.

Northwestern University SuperAging Program (NUSAP)

The purpose of this study is to identify factors that contribute to the maintenance of functioning in old age (age 80 and above). We will be looking at a variety of factors including cognition, personality traits, psychosocial factors, genetic factors, and brain structure. The second purpose of this study is to look at how performance on these variables changes over time.

BenfoTeam

The BenfoTeam clinical research trial aims to increase the amount of thiamine (vitamin B1) in the brain to show cognitive decline in people with mild cognitive impairment and mild Alzheimer's disease (AD). 

This trial is designed for people who are age 50-89 and are experiencing significant memory concerns or those of whom have already been diagnosed with Mild Cognitive Impairment (MCI) or mild AD. This stage of the disease, MCI through mild AD, is also known as early AD. 

CLARiTI

ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) is an exciting new study that will move us towards better understanding, treatment, and prevention of Alzheimer's disease and related dementias (ADRD).

CLARiTI’s mission is to uncover the intersecting causes of memory and thinking problems through collecting brain imaging data and blood test data.